Actively Recruiting
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Led by Xencor, Inc. · Updated on 2026-05-06
270
Participants Needed
57
Research Sites
220 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Brief summary The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).
CONDITIONS
Official Title
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Parts A and B: Age 18 to 55 years
- Parts A and B: Must be in good health with no significant medical history
- Parts A and B: Clinical laboratory values within normal range
- Parts A and B: Body mass index (BMI) between 18 and 35 inclusive
- Parts A and B: Use of contraception consistent with local regulations
- Parts A and B: Able and willing to provide written informed consent
- Part C: Age 18 to 75 years
- Part C: Must be in good health with no significant medical history
- Part C: Ulcerative colitis diagnosis at least 3 months prior to screening
- Part C: Moderately to severely active ulcerative colitis defined by modified Mayo score ≥ 5, Mayo endoscopic score ≥ 2, and rectal bleeding subscore ≥ 1
- Part C: Ulcerative colitis extending at least 15 cm from the anal verge confirmed by colonoscopy
- Part C: Inadequate response, loss of response, or intolerance to at least one conventional or advanced therapy for ulcerative colitis
- Part C: Able and willing to provide written informed consent
You will not qualify if you...
- Parts A and B: Any physical or psychological condition that prevents study completion
- Parts A and B: History of suicidal behavior or suicidal thoughts
- Parts A and B: Heavy use of nicotine-containing products
- Parts A and B: Positive for HIV, hepatitis B, or hepatitis C
- Parts A and B: Cardiac arrhythmia or clinically significant abnormal ECG
- Parts A and B: Active use of prescription medications within 14 days before Day -1
- Parts A and B: Active use of over-the-counter or herbal medications within 7 days before screening
- Parts A and B: Use of other investigational products within 30 days
- Parts A and B: Blood or plasma donation within 60 days
- Parts A and B: Pregnant or breastfeeding
- Part C: Any physical or psychological condition that prevents study participation
- Part C: Diagnosis of Crohn disease, indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or diverticular disease with colitis
- Part C: Positive test for Clostridium difficile toxins
- Part C: Positive for HIV, hepatitis B, or hepatitis C
- Part C: Cardiac arrhythmia or clinically significant abnormal ECG
- Part C: Pregnant or breastfeeding
- Other protocol defined inclusion/exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 57 locations
1
Xencor Investigative Site
Scottsdale, Arizona, United States, 85255
Actively Recruiting
2
Xencor Investigative Site
Bradenton, Florida, United States, 34209
Actively Recruiting
3
Xencor Investigative Site
Brandon, Florida, United States, 33511
Actively Recruiting
4
Xencor Investigative Site
Jacksonville, Florida, United States, 32258
Actively Recruiting
5
Xencor Investigative Site
Kissimmee, Florida, United States, 34741
Actively Recruiting
6
Xencor Investigative Site
Margate, Florida, United States, 33063
Actively Recruiting
7
Xencor Investigative Site
Palmetto Bay, Florida, United States, 33176
Actively Recruiting
8
Xencor Investigative Site
Tampa, Florida, United States, 33613
Actively Recruiting
9
Xencor Investigative Site
Louisville, Kentucky, United States, 40218
Actively Recruiting
10
Xencor Investigative Site
Raleigh, North Carolina, United States, 27612
Actively Recruiting
11
Xencor Investigative Site
Beavercreek, Ohio, United States, 45440
Actively Recruiting
12
Xencor Investigative Site
Denton, Texas, United States, 76201
Actively Recruiting
13
Xencor Investigative Site
Georgetown, Texas, United States, 78628
Actively Recruiting
14
Xencor Investigative Site
Houston, Texas, United States, 77024
Actively Recruiting
15
Xencor Investigative Site
Houston, Texas, United States, 77090
Actively Recruiting
16
Xencor Investigative Site
Kingwood, Texas, United States, 77339
Actively Recruiting
17
Xencor Investigative Site
Lubbock, Texas, United States, 79424
Actively Recruiting
18
Xencor Investigative Site
San Antonio, Texas, United States, 78229
Actively Recruiting
19
Xencor Investigative Site
Tyler, Texas, United States, 75701
Actively Recruiting
20
Xencor Investigative Site
Wollongong, New South Wales, Australia, 2500
Actively Recruiting
21
Xencor Investigative Site
South Brisbane, Queensland, Australia, 4101
Actively Recruiting
22
Xencor Investigative Site
Southport, Queensland, Australia, 4215
Actively Recruiting
23
Xencor Investigative Site
Joondalup, Western Australia, Australia, 6027
Completed
24
Xencor Investigative Site
Nedlands, Western Australia, Australia, 6009
Completed
25
Xencor Investigative Site
Sofia, Bulgaria, 1618
Actively Recruiting
26
Xencor Investigative Site
Vancouver, British Columbia, Canada, V6Z 2K5
Actively Recruiting
27
Xencor Investigative Site
London, Ontario, Canada, N6K 1M5
Actively Recruiting
28
Xencor Investigative Site
Scarborough Village, Ontario, Canada, M1S4T7
Actively Recruiting
29
Xencor Investigative Site
Montreal, Quebec, Canada, H3H 1EB
Actively Recruiting
30
Xencor Investigative Site
Rijeka, Croatia, 51000
Actively Recruiting
31
Xencor Investigative Site
Zagreb, Croatia, 10000
Actively Recruiting
32
Xencor Investigative Site
Tbilisi, Georgia, 0112
Actively Recruiting
33
Xencor Investigative Site
Thessaloniki, Greece, 54642
Actively Recruiting
34
Xencor Investigative Site
Budapest, Hungary, 1136
Actively Recruiting
35
Xencor Investigative Site
Vác, Hungary, 2600
Actively Recruiting
36
Xencor Investigative Site
Chisinau, Moldova
Actively Recruiting
37
Xencor Investigative Site
Wroclaw, Lower Silesian Voivodeship, Poland, 53-611
Actively Recruiting
38
Xencor Investigative Site
Warsaw, Mazonian, Poland, 00-189
Actively Recruiting
39
Xencor Investigative Site
Sopot, Pomeranian Voivodeship, Poland, 81-756
Actively Recruiting
40
Xencor Investigative Site
Bydgoszcz, Poland, 85-079
Actively Recruiting
41
Xencor Investigative Site
Katowice, Poland, 40-748
Actively Recruiting
42
Xencor Investigative Site
Staszów, Poland, 28-200
Actively Recruiting
43
Xencor Investigative Site
Szczecin, Poland, 71-685
Actively Recruiting
44
Xencor Investigative Site
Warsaw, Poland, 004-501
Actively Recruiting
45
Xencor Investigative Site
Bucharest, District 1, Romania, 01-1658
Actively Recruiting
46
Xencor Investigative Site
Cluj-Napoca, Romania, 400006
Actively Recruiting
47
Xencor Investigative Site
Lutsk, Volyn Oblast, Ukraine, 43005
Actively Recruiting
48
Xencor Investigative Site
Ivano-Frankivsk, Ukraine, 76008
Actively Recruiting
49
Xencor Investigative Site
Kyiv, Ukraine, 01135
Actively Recruiting
50
Xencor Investigative Site
Kyiv, Ukraine, 02091
Actively Recruiting
51
Xencor Investigative Site
Lviv, Ukraine, 79000
Actively Recruiting
52
Xencor Investigative Site
Lviv, Ukraine, 79010
Actively Recruiting
53
Xencor Investigative Site
Lviv, Ukraine, 79059
Actively Recruiting
54
Xencor Investigative Site
Uzhhorod, Ukraine, 88000
Actively Recruiting
55
Xencor Investigative Site
Vinnytsia, Ukraine, 21009
Actively Recruiting
56
Xencor Investigative Site
Vinnytsia, Ukraine, 21028
Actively Recruiting
57
Xencor Investigative Site
Zhytomyr, Ukraine, 10001
Actively Recruiting
Research Team
S
Sudeepta Aggarwal
CONTACT
M
Mark Osterman, MD, MSCE
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here